March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving scanning access through increased production capacity.
Advertisement
(Reporting by Sahil Pandey, Puyaan Singh and Kamal Choudhury in Bengaluru; Editing by Sahal Muhammed)
